ESTRO Brachytherapy for Prostate Cancer 2018

The controversy !

Point: the relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: is there an elephant in the room? Morris WJ , Halperin R , Spadinger I .

Counterpoint: there is a dose-response relationship in the low-dose rate brachytherapy management of prostate cancer. Stock RG .

Brachytherapy. 2010 Oct-Dec;9(4):289-92; discussion 297-8.